CARA - Cara Therapeutics, Inc.
| Previous Close | 23.35 |
| Open | 23.62 |
| Bid | 23.61 x 800 |
| Ask | 23.65 x 800 |
| Day's Range | 23.26 - 23.79 |
| 52 Week Range | 12.19 - 27.55 |
| Volume | 457,758 |
| Avg. Volume | 896,501 |
| Market Cap | 1.097B |
| Beta (3Y Monthly) | 2.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.17 |
| Earnings Date | Aug 7, 2019 - Aug 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.90 |
- Simply Wall St.
Does Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Pay Reflect Performance?
Derek Chalmers became the CEO of Cara Therapeutics, Inc. (NASDAQ:CARA) in 2004. First, this article will compare CEO...
- Thomson Reuters StreetEvents
Edited Transcript of CARA earnings conference call or presentation 7-Aug-19 8:30pm GMT
Q2 2019 Cara Therapeutics Inc Earnings Call
- Motley Fool
Here's Why Cara Therapeutics Rose 11.3% in July
The development-stage pharma company started an important clinical trial.
- Motley Fool
Only These 9 Cannabis Stocks Rose in July
While these nine pot stocks rose, 38 others ended lower by at least 10%.
- GlobeNewswire
Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019
STAMFORD, Conn., July 31, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.
- Investopedia
Top Marijuana Stocks on the NASDAQ
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
- GlobeNewswire
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
STAMFORD, Conn., July 29, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical.
- Motley Fool
Weekly Cannabis Stock News: Auxly's Surprise Strategic Partner Investment
A traditional tobacco company takes a stake in Auxly, while heads roll at CannTrust Holdings.
- Motley Fool
Cara Therapeutics Floats New Stock Issue
The company will issue 5 million shares to raise capital for its Korsuva pipeline drug.
- GlobeNewswire
Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock
STAMFORD, Conn., July 24, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical.
- GlobeNewswire
Cara Therapeutics Announces Proposed Offering of Common Stock
Cara Therapeutics, Inc. (CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. In addition, Cara Therapeutics expects to grant certain of the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- GlobeNewswire
Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment
- Study now fully enrolled; topline data expected in 4Q 2019 - STAMFORD, Conn., July 22, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on.
- GuruFocus.com
Cara Therapeutics Inc (CARA) CFO & Chief Strategy Officer Mani Mohindru Sold $935,775 of Shares
CFO & Chief Strategy Officer of Cara Therapeutics Inc (30-Year Financial, Insider Trades) Mani Mohindru (insider trades) sold 37,431 shares of CARA on 07/15/2019 at an average price of $25 a share. Continue reading...
- TipRanks
4 ‘Strong Buy’ Biotechs With Big 3Q19 Catalysts
Investing in biotech stocks can generate substantial returns. If data results meet key targets, or drug applications are accepted, share prices can soar. Unfortunately the reverse is also true. That means investors have to be particularly careful when it comes to biotech stocks. The following four stocks all show a Strong Buy Street consensus- based on ratings received over the last three months. They also boast significant upcoming catalysts this quarter- that could potentially send share prices soaring. Let’s take a closer look at each stock now: 1\. Intercept Pharmaceuticals (ICPT)Intercept Pharma is trying to help patients with progressive non-viral liver diseases. The company already has one drug on the market (for primary biliary cirrhosis), and recently released positive results from the Phase 3 REGENERATE trial in NASH Fibrosis. Nash is a chronic condition in which the buildup of fat and inflammation in the liver may eventually lead to severe scarring called fibrosis. It is currently the second leading cause of liver transplant in the US- making it a very lucrative opportunity for drug companies. Intercept has an early mover advantage here. The company plans to submit an NDA [new drug application] in 3Q19 and an MAA [marketing authorization application] in 4Q19. “Obeticholic Acid will likely be the first to market in NASH and is the only drug to have demonstrated a fibrosis benefit” cheers Needham analyst Alan Carr. “We acknowledge certain potential safety and tolerability limitations, but nevertheless expect the drug to have an important role in NASH therapy over the next several years” says the analyst. Overall the stock has a ‘Strong Buy’ Street consensus, with 5 recent buy ratings vs just 1 hold rating. Meanwhile the average analyst price target of $148 indicates huge upside potential of 113%. >>Click Here to see the full list of ICPT Analyst Ratings 2\. Rhythm Pharmaceuticals (RYTM)Rhythm is developing treatments for rare genetic deficiencies that result in life-threatening metabolic disorders. The big news here is that Rhythm is expected to announce results in 3Q19 from two Phase 3 trials of setmelanotide in POMC and LEPR Deficiency. There are currently no approved drugs for these diseases- and no other drugs in development.“We anticipate a positive outcome for both trials based on Phase 2 data demonstrating a profound and durable impact on appetite and weight” writes Carr. The analyst assumes US approval and launch in 4Q20 (EU 2021) and peak worldwide sales of around $265M in 2032.“Considering recent weakness, we believe the stock is attractive ahead of Phase 3 POMC and LEPR Deficiency trial results. We believe there is even more room for upside for the stock as the company completes label expansion trials in 2020+” enthuses Carr. Most notably label expansion Phase 3 trial in Bardet-Biedl/Alstrom Syndromes remains on track for results in 2H20. Success here adds another $485M in peak sales potential. “Additional patient populations under evaluation in a Phase 2 trial push peak sales above $1B” writes Carr. RYTM has four consecutive recent buy ratings from the Street, with an average price target of $40 (95% upside potential). >>Click Here to see the full list of RYTM Analyst Ratings 3\. Moderna Inc (MRNA)Moderna is hoping to create a new generation of transformative medicines for patients. The company’s approach is to use mRNA medicines to instruct a patient’s own cells to produce proteins that could prevent, treat, or cure disease. Encouragingly, all seven analysts covering MRNA rate the stock a buy- so no hold or sell ratings here. “We expect Moderna to provide updates on Cytomegalovirus (CMV), Chikungunya, and Methylmalonic Acidemia (MMA) programs by YE19” writes the analyst.While the commercial opportunity in Chikungunya is modest, he believes PK/PD data from the Phase 1 trial will provide valuable insight into the overall predictability of several other mRNA drugs in development at the company.“The stock has fallen substantially from its peak in May 2019. We believe there is an opportunity for upside in 2H19 as the company announces data from the above CMV, Chikungunya, and MMA programs” Carr concludes. Indeed, the Street’s $30 average price target suggests share prices can double in the coming months. >>Click Here to see the full list of MRNA Analyst Ratings 4\. Cara Therapeutics (CARA)Cara Therapeutics has surged 30% in last the three months. In May the company announced positive results from the first of two Phase 3 trials of IV Korsuva in Chronic Kidney Disease (CKD) dialysis patients with pruritus. Pruritus refers to the severe itching of the skin, a common and distressing symptom for patients with chronic kidney disease. Cara Therapeutics CEO Derek Chalmers noted at the time that the company was "particularly encouraged by the early [anti-itching] response with Korsuva injection." Now investors are keeping a close eye on results from the second trial (KALM-2) and from a Phase 2 trial of oral Korsuva in non-dialysis patients with CKD pruritus- both expected in 2H19. “We anticipate a positive outcome for both trials” comments Carr, adding that the recent results point to a favorable outcome for the KALM-2 trial. “We believe the outcome is also a positive indicator for the oral Korsuva programs in CKD pruritus, Liver Disease pruritus, and Atopic Dermatitis, all of which have large commercial opportunities.”Bottom line: “The stock is substantially undervalued.” All six analysts polled are bullish on CARA right now. Meanwhile the average analyst price target stands at $33 (30% upside potential). >>Click Here to see the full list of CARA Analyst RatingsDiscover the latest ratings from top analysts in any sector you choose
- Motley Fool
3 Top Biotech Stocks to Buy for the 2nd Half of 2019
Great growth prospects and relatively modest risk levels make these biotech stocks really attractive.
- Simply Wall St.
Estimating The Fair Value Of Cara Therapeutics, Inc. (NASDAQ:CARA)
Does the July share price for Cara Therapeutics, Inc. (NASDAQ:CARA) reflect what it's really worth? Today, we will...
- GuruFocus.com
GuruFocus Value Idea Contest Sees 2 Winners!
Two entries to the contest have already more than doubled, winning their authors $1,000 each Continue reading...
- PR Newswire
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis
Oral KORSUVA is now the subject of three separate, ongoing Phase 2 clinical trials BOONTON, N.J. , July 11, 2019 /PRNewswire/ -- Enteris BioPharma, Inc. , a biotechnology company developing innovative ...
- GlobeNewswire
Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA™ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis
STAMFORD, Conn., July 09, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.
- Motley Fool
Better Buy: GW Pharmaceuticals vs. Cara Therapeutics
Which one of these unconventional drugmakers can give your portfolio the biggest boost?
- GlobeNewswire
Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAᵀᴹ (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the initiation of a Phase 2 trial of Oral KORSUVA (CR845/difelikefalin) for the treatment of pruritus in patients with hepatic impairment due to primary biliary cholangitis (PBC).
- Investopedia
Understanding Medical Cannabis vs. Recreational Cannabis Stocks
Medical marijuana and recreational marijuana are two high growth sectors in the cannabis industry. Learn about how the two differ, and how you can get into the market.
- Motley Fool
Is Cara Therapeutics a Buy Now?
A pivotal trial for the company's lead candidate was an unequivocal success.
- MarketWatch
Cara Therapeutics surges 15.7% after company announces positive late-stage data for itchiness treatment
The company reported that dialysis patients experiencing itchiness who were given its Korsuva injection showed statistically significant improvement compared with those on placebo.
- GlobeNewswire
Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference
STAMFORD, Conn., May 31, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
